Ribo Life Science files EU Phase I clinical trial application for dual-target siRNA SR122
November 10, 2026
Source: drugdu
38
On November 10, Ribo Life Science (06938.HK) announced in a voluntary disclosure that it had filed a Phase I clinical trial application in the European Union for its in-house candidate SR122 injection. SR122 is a GalNAc-conjugated small interfering RNA (siRNA) therapy that targets both ApoC3 and PCSK9. It is being developed for dyslipidemia, including severe hypertriglyceridemia and mixed dyslipidemia.
The planned Phase I study will be randomized and placebo-controlled. It will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered SR122 in healthy volunteers.
Source: https://finance.eastmoney.com/a/202611103926814664.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Tigermed to Privatize Frontage at HK$2.37 per Share, a ~59.1% Premium, and Divest Overseas Lab Business November 10, 2026
- argenx to Acquire Unnatural Products for Up to Approximately $1.15 Billion, Adding Peptide Discovery Engine November 10, 2026
- Henlius’s HLX11 Approved in Brazil as the Country’s First Pertuzumab Biosimilar November 10, 2026
- Lunan Pharmaceutical’s Shuerte® Thioctic Acid Tablets have been approved for marketing! November 10, 2026
- $455 million! Boston Scientific ramps up its investment in heart pumps. November 10, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
